US Surgical's sales and margins improve
This article was originally published in Clinica
US Surgical continued its improvement in sales and operating results during 1995. Turnover rose 11% to $1,022 million and gross margins increased to 56% of sales, a rise of 6% over 1994.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.